StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Non-GAAP Total Operating Expenses by Year

Non-GAAP Total Operating Expenses ($M) ($M)

Amgen Non-GAAP Total Operating Expenses: $20,548M in FY2025, up 11.7% from a year earlier. That is the highest of the 9 years on record here.

Latest, FY2025
20,548
Period ended Dec 31, 2025
Change on a year earlier
+11.7%
18,396 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| Non-GAAP operating expenses | $ | 5,860 | $ | 5,053 | $ | 20,548 | $ | 18,396”

Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗

Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up non-GAAP Total Operating Expenses

Cite this data

StockData. (2026). Amgen Non-GAAP Total Operating Expenses ($M), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/ng-opex

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.